AQST

Upgrade to FINVIZ Elite to get real-time quotes, intraday charts, and advanced charting tools. Subscribe to Elite

Jan 09, 7:07 AMAquestive Therapeutics said today the FDA identified deficiencies in its Anaphylm NDA, pausing labeling discussions and potentially delaying approval ahead of the Jan 31 PDUFA date, and the company ended 2025 with $120 million in cash.

Peers: APLS XOMA BPMC CRSP ASND ACRS MGNX MDGL GLPG GERN

| Held by: VTI IWM VXF IWN XPH VTWO IWO IWC ITOT VFMO

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-0.70	Insider Own	6.36%	Shs Outstand	121.66M	Perf Week	-39.38%
Market Cap	757.64M	Forward P/E	-	EPS next Y	-0.53	Insider Trans	-2.20%	Shs Float	114.24M	Perf Month	-35.90%
Enterprise Value	757.44M	PEG	-	EPS next Q	-0.13	Inst Own	51.22%	Short Float	19.19%	Perf Quarter	-41.55%
Income	-68.98M	P/S	17.46	EPS this Y	-21.35%	Inst Trans	12.05%	Short Ratio	7.95	Perf Half Y	-2.49%
Sales	43.40M	P/B	-	EPS next Y	14.72%	ROA	-50.44%	Short Interest	21.92M	Perf YTD	-39.47%
Book/sh	-0.03	P/C	5.87	EPS next 5Y	23.31%	ROE	-	52W High	7.55 -48.21%	Perf Year	21.43%
Cash/sh	0.67	P/FCF	-	EPS past 3/5Y	34.99% 27.90%	ROIC	-59.33%	52W Low	2.12 84.43%	Perf 3Y	339.33%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	4.23% 1.82%	Gross Margin	60.28%	Volatility	7.37% 5.39%	Perf 5Y	-29.42%
Dividend TTM	-	EV/Sales	17.45	EPS Y/Y TTM	-56.55%	Oper. Margin	-128.56%	ATR (14)	0.49	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	5.62	Sales Y/Y TTM	-26.32%	Profit Margin	-158.95%	RSI (14)	21.84	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	5.93	EPS Q/Q	-10.52%	SMA20	-34.76%	Beta	1.65	Target Price	8.62
Payout	-	Debt/Eq	-	Sales Q/Q	-5.43%	SMA50	-35.12%	Rel Volume	15.74	Prev Close	6.21
Employees	142	LT Debt/Eq	-	Earnings	Nov 05 AMC	SMA200	-13.20%	Avg Volume	2.76M	Price	3.91
IPO	Jul 25, 2018	Option/Short	Yes / Yes	EPS/Sales Surpr.	-9.38% -1.24%	Trades		Volume	43,406,107	Change	-37.04%

Date	Action	Analyst	Rating Change	Price Target Change
Jun-02-25	Resumed	Oppenheimer	Outperform	$7
Dec-17-24	Initiated	Cantor Fitzgerald	Overweight	$17
May-10-24	Initiated	Leerink Partners	Outperform	$8
Apr-11-24	Initiated	Piper Sandler	Overweight	$10
Mar-28-24	Initiated	Raymond James	Outperform	$7
Apr-07-21	Resumed	RBC Capital Mkts	Outperform	$7
Apr-22-19	Initiated	H.C. Wainwright	Buy
Jan-03-19	Initiated	Lake Street	Buy	$14
Aug-20-18	Initiated	RBC Capital Mkts	Outperform	$23
Aug-20-18	Initiated	JMP Securities	Mkt Outperform	$29

Jan-10-26 09:00AM	Morning Movers: Oklo, Vistra climb following Meta nuclear energy deals (TipRanks)
Jan-09-26 12:32PM	Bad News For Competitor Turns Into Big Win For ARS Pharma Stock (Benzinga) -37.04%
11:28AM	Aquestive Stock Slides After FDA Flags Issues With Allergy Drug Application (Benzinga)
07:00AM	Aquestive Therapeutics Announces Regulatory Development for Anaphylm (dibutepinephrine) Sublingual Film and Provides Business Update (GlobeNewswire)
Jan-07-26 12:00PM	Aquestive Therapeutics (AQST) Upgraded to Buy: Here's Why (Zacks)
07:00AM	Loading…
Nov-24-25 07:00AM	Aquestive Therapeutics to Participate in the Piper Sandler 37th Annual Healthcare Conference (GlobeNewswire)
Nov-13-25 12:09PM	Jim Cramer on Aquestive Therapeutics: "I Think It's a Very Interesting Spec" (Insider Monkey) -5.02%
Nov-11-25 08:35PM	Lightning Round: Joby Aviation is losing too much money, says Jim Cramer (CNBC TV)
Nov-06-25 02:09PM	Aquestive Therapeutics Inc (AQST) Q3 2025 Earnings Call Highlights: Navigating Challenges and ... (GuruFocus.com)
Nov-05-25 06:00PM	Here's What Key Metrics Tell Us About Aquestive Therapeutics (AQST) Q3 Earnings (Zacks)
05:35PM	Aquestive Therapeutics (AQST) Reports Q3 Loss, Lags Revenue Estimates (Zacks)
04:37PM	Aquestive Therapeutics: Q3 Earnings Snapshot (Associated Press Finance)
04:01PM	Aquestive Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update (GlobeNewswire)
07:44AM	Aquestive Therapeutics Inc (AQST) Q3 2025 Earnings Report Preview: What To Expect (GuruFocus.com)
Nov-04-25 08:14AM	Aquestive Therapeutics Inc (AQST) Q3 2025 Earnings Report Preview: What To Look For (GuruFocus.com) -6.32%
07:00AM	Loading…
07:00AM	Aquestive Therapeutics Announces Leadership Expansion to Support Growth (GlobeNewswire)
Nov-03-25 07:00AM	Aquestive Therapeutics to Participate in a Fireside Chat Hosted by Piper Sandler (GlobeNewswire)
Oct-31-25 09:40AM	Is DBV Technologies (DBVT) Stock Outpacing Its Medical Peers This Year? (Zacks)
Oct-30-25 07:00AM	Aquestive Therapeutics to Attend 2025 ACAAI Annual Meeting (GlobeNewswire)
Oct-27-25 07:00AM	Aquestive Therapeutics to Report Third Quarter 2025 Financial Results and Recent Business Highlights on November 5 and Host Conference Call on November 6 at 8:00 a.m. ET (GlobeNewswire)
Oct-15-25 09:40AM	Are Medical Stocks Lagging Aquestive Therapeutics (AQST) This Year? (Zacks) +6.69%
Oct-10-25 08:59AM	Aquestive Therapeutics (AQST) Surges 7.9%: Is This an Indication of Further Gains? (Zacks)
Oct-08-25 07:00AM	Aquestive Therapeutics Broadens Patent Estate for Anaphylm (GlobeNewswire)
Sep-22-25 04:37AM	Aquestive Therapeutics (AQST) Soars 14.8%: Is Further Upside Left in the Stock? (Zacks) -8.82%
03:42AM	Jim Cramer on Aquestive Therapeutics: "I think it's Worth Taking a Chance On" (Insider Monkey)
Sep-05-25 11:00AM	AQST Stock Up as FDA Skips Advisory Meeting to Discuss Anaphylm NDA (Zacks) +7.11%
Sep-04-25 12:44PM	FDA Confirms Direct Review Path For Aquestive's Allergy Treatment (Benzinga) +28.10%
07:00AM	Aquestive Therapeutics Announces that FDA Will Not Require an Advisory Committee Meeting to Discuss New Drug Application for Anaphylm (GlobeNewswire)
Aug-26-25 07:00AM	Aquestive Therapeutics to Participate in Upcoming September Investor Conferences (GlobeNewswire)
Aug-18-25 06:57AM	Aquestive signs $75m agreement for launch of Anaphylm (Pharmaceutical Technology)
09:40AM	Loading…
Aug-14-25 09:40AM	Is Aquestive Therapeutics (AQST) Stock Outpacing Its Medical Peers This Year? (Zacks)
06:28AM	Aquestive Therapeutics Announces Pricing of $85 Million Underwritten Offering of Common Stock (GlobeNewswire)
06:00AM	Aquestive Therapeutics Announces $75M Strategic Funding Agreement with RTW to Support the Potential Launch of Anaphylm (epinephrine) Sublingual Film (GlobeNewswire)
Aug-11-25 07:30PM	Compared to Estimates, Aquestive Therapeutics (AQST) Q2 Earnings: A Look at Key Metrics (Zacks)
06:55PM	Aquestive Therapeutics (AQST) Reports Q2 Loss, Lags Revenue Estimates (Zacks)
06:07PM	Aquestive Therapeutics: Q2 Earnings Snapshot (Associated Press Finance)
04:01PM	Aquestive Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update (GlobeNewswire)
09:32AM	Aquestive Therapeutics Inc (AQST) Q2 2025: Everything You Need To Know Ahead Of Earnings (GuruFocus.com)
Aug-08-25 09:25AM	Aquestive Therapeutics Inc (AQST) Q2 2025 Earnings Report Preview: What To Expect (GuruFocus.com)
Aug-04-25 07:00AM	Aquestive Therapeutics to Report Second Quarter 2025 Financial Results and Recent Business Highlights on August 11 and Host Conference Call on August 12 at 8:00 a.m. ET (GlobeNewswire) +5.24%
Jul-22-25 05:20PM	USANA Health Sciences (USNA) Q2 Earnings and Revenues Top Estimates (Zacks) -6.15% +7.30%
07:00AM	Aquestive Therapeutics Names Sherry Korczynski as Chief Commercial Officer (GlobeNewswire)
Jul-15-25 07:00AM	Aquestive Therapeutics Provides International Expansion Update for Anaphylm (epinephrine) Sublingual Film (GlobeNewswire)
Jul-07-25 07:00AM	Aquestive Therapeutics to Participate in Leerink Partners Therapeutics Forum: I&I and Metabolism (GlobeNewswire)
Jul-02-25 10:06PM	H.C. Wainwright Reaffirms Buy on Aquestive Therapeutics, Inc. (AQST) After FDA Approval (Insider Monkey) +8.24%
Jun-25-25 07:00AM	Aquestive Therapeutics to Present Positive Data from Pharmacokinetic and Pharmacodynamic Studies of Anaphylm (epinephrine) Sublingual Film at the CFAAR Food Allergy Summit (GlobeNewswire)
Jun-24-25 08:50AM	These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar (Zacks)
Jun-16-25 07:00AM	Aquestive Therapeutics Announces FDA Acceptance of New Drug Application and PDUFA Date for Anaphylm for the Treatment of Severe Allergic Reactions (GlobeNewswire)
May-21-25 11:17AM	Aquestive Therapeutics, Inc. (AQST): Analysts See 245% Upside Potential (Insider Monkey) -5.02%
May-14-25 03:05AM	Aquestive Therapeutics Inc (AQST) Q1 2025 Earnings Call Highlights: Navigating Revenue Declines ... (GuruFocus.com)
May-12-25 05:30PM	Aquestive Therapeutics (AQST) Reports Q1 Earnings: What Key Metrics Have to Say (Zacks) -19.65%
05:15PM	Aquestive Therapeutics (AQST) Reports Q1 Loss, Lags Revenue Estimates (Zacks)
04:08PM	Aquestive Therapeutics: Q1 Earnings Snapshot (Associated Press Finance)
04:01PM	Aquestive Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update (GlobeNewswire)
09:38AM	Earnings To Watch: Aquestive Therapeutics Inc (AQST) Reports Q1 2025 Result (GuruFocus.com)
May-09-25 09:40AM	Aquestive Therapeutics Inc (AQST) Q1 2025: Everything You Need To Know Ahead Of Earnings (GuruFocus.com)
May-08-25 05:15PM	Collegium Pharmaceutical (COLL) Q1 Earnings and Revenues Surpass Estimates (Zacks)
May-05-25 07:00AM	Aquestive Therapeutics to Participate in Citizens Life Sciences Conference (GlobeNewswire) -5.67%
May-04-25 04:32PM	Aquestive Therapeutics: Unprofitable For A Few More Years, But Significant Upside Potential (Seeking Alpha)
May-01-25 07:00AM	Aquestive Therapeutics to Report First Quarter 2025 Financial Results and Recent Business Highlights on May 12 and Host Conference Call on May 13 at 8:00 a.m. ET (GlobeNewswire)
Apr-14-25 09:09AM	Strength Seen in Recursion Pharmaceuticals (RXRX): Can Its 27.7% Jump Turn into More Strength? (Zacks)
Apr-09-25 07:00AM	Aquestive Therapeutics to Participate in Piper Sandler Spring Biopharma Symposium (GlobeNewswire) +8.86%
Apr-01-25 07:00AM	Aquestive Therapeutics Announces Positive Topline PK Results from its Pediatric Study and Completes the NDA Submission for Anaphylm (epinephrine) Sublingual Film (GlobeNewswire)
Mar-25-25 08:35AM	Aquestive Therapeutics: Oral Anaphylaxis NDA Opportunity Spells Buy (SeekingAlpha)
Mar-24-25 05:37AM	Aquestive Therapeutics: Not For Me, But Attractive (SeekingAlpha)
Mar-07-25 02:07AM	Aquestive Therapeutics Inc (AQST) Q4 2024 Earnings Call Highlights: Strategic Advances Amid ... (GuruFocus.com)
Mar-05-25 06:30PM	Compared to Estimates, Aquestive Therapeutics (AQST) Q4 Earnings: A Look at Key Metrics (Zacks) -7.53%
05:10PM	Aquestive Therapeutics (AQST) Reports Q4 Loss, Lags Revenue Estimates (Zacks)
04:18PM	Aquestive Therapeutics: Q4 Earnings Snapshot (Associated Press Finance)
04:01PM	Aquestive Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update (GlobeNewswire)
07:26AM	What To Expect From Aquestive Therapeutics Inc (AQST) Q4 2024 Earnings (GuruFocus.com)
Mar-04-25 07:21AM	Aquestive Therapeutics Inc (AQST) Q4 2024: Everything You Need To Know Ahead Of Earnings (GuruFocus.com)
Feb-26-25 07:00AM	Aquestive Therapeutics to Participate in Two Upcoming Conferences in March (GlobeNewswire)
Feb-20-25 07:00AM	Aquestive Therapeutics to Report Fourth Quarter 2024 Financial Results and Recent Business Highlights on March 5 and Host Conference Call on March 6 at 8:00 a.m. ET (GlobeNewswire)
Feb-12-25 07:00AM	Aquestive Therapeutics to Present New Findings on Anaphylm (Epinephrine Sublingual Film) at the 2025 AAAAI Annual Meeting (GlobeNewswire) +14.14%
Feb-04-25 07:00AM	Aquestive Therapeutics to Participate in Oppenheimer 35th Annual Healthcare Conference (GlobeNewswire) +6.23%
Jan-13-25 07:00AM	Aquestive Therapeutics Provides Business Update and Outlines Key 2025 Objectives (GlobeNewswire)
Dec-19-24 11:40AM	Aquestive Therapeutics Gains FDA Orphan Drug Exclusivity for Pediatric Seizure Treatment (GuruFocus.com) +5.20%
08:00AM	Aquestive Therapeutics Receives U.S. FDA Orphan Drug Exclusivity for Libervant (diazepam) Buccal Film in Pediatric Patients with Seizure Clusters Ages Two to Five (GlobeNewswire)
Dec-17-24 01:56PM	Developer Of EpiPen Alternative Aquestive Stock Undervalued Despite Strong Clinical Data, Analyst Sees Huge Upside (Benzinga) +6.94%
Dec-02-24 08:00AM	Aquestive Therapeutics Announces Positive FDA Feedback and Reaffirms NDA Submission Guidance for Anaphylm (epinephrine) Sublingual Film (GlobeNewswire) -5.50%
Nov-16-24 01:25AM	Is Aquestive Therapeutics (AQST) the Best Multibagger Stock to Buy Heading into 2025? (Insider Monkey)
Nov-12-24 08:00AM	Aquestive Therapeutics to Participate in Two Upcoming Investor Conferences (GlobeNewswire)
Nov-06-24 02:07AM	Aquestive Therapeutics Inc (AQST) Q3 2024 Earnings Call Highlights: Navigating Growth Amidst ... (GuruFocus.com) +6.62%
Nov-04-24 07:00PM	Aquestive Therapeutics (AQST) Q3 Earnings: How Key Metrics Compare to Wall Street Estimates (Zacks) -6.70% -7.67%
05:50PM	Aquestive Therapeutics (AQST) Reports Q3 Loss, Tops Revenue Estimates (Zacks)
04:48PM	Aquestive Therapeutics: Q3 Earnings Snapshot (Associated Press Finance)
04:36PM	Aquestive Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update (GlobeNewswire)
07:11AM	Aquestive Therapeutics Inc (AQST) Q3 2024 Earnings Report Preview: What To Expect (GuruFocus.com)
Nov-01-24 09:07AM	Aquestive Therapeutics Inc (AQST) Q3 2024: Everything You Need To Know Ahead Of Earnings (GuruFocus.com)
Oct-25-24 08:29AM	Aquestive Therapeutics Breakthrough in Allergy Treatment Study (TipRanks)
08:00AM	Aquestive Therapeutics to Present Subsequent Analysis of Pivotal Study for Anaphylm (epinephrine) Sublingual Film Demonstrating Comparable PK and PD Data to Epinephrine Injection Regardless of Variable Placement or Intraoral Movement at American College of Allergy Asthma and Immunology (ACAAI) 2024 Annual Meeting (GlobeNewswire)
Oct-24-24 08:00AM	Aquestive Therapeutics Announces Positive Topline Results from Oral Allergy Syndrome (OAS) Challenge Study for Anaphylm (epinephrine) Sublingual Film (GlobeNewswire)
Oct-21-24 08:00AM	Aquestive Therapeutics to Report Third Quarter 2024 Financial Results and Recent Business Highlights on November 4 and Host Conference Call on November 5 at 8:00 a.m. ET (GlobeNewswire)
Sep-30-24 02:25PM	Optimism Around Aquestive As it Moves Forward With Severe Allergy, Baldness Candidate (Benzinga) +5.51%
Sep-27-24 08:30AM	Aquestive Therapeutics Spotlights its Innovative Epinephrine Delivery Pipeline at Virtual Investor Day (GlobeNewswire) -5.60%
Sep-09-24 08:15AM	Aquestive Therapeutics to Hold Virtual Investor Day to Provide Pipeline Updates on September 27th (GlobeNewswire) +12.20%
Aug-22-24 08:00AM	Aquestive Therapeutics to Participate in Two Upcoming Investor Conferences (GlobeNewswire) -7.31%
Aug-14-24 08:00AM	Aquestive Therapeutics Comments on Recent FDA Approval of Non-Injection-Based Epinephrine Product for the Treatment of Anaphylaxis and Reiterates Expected Timing for NDA Filing of Anaphylm (GlobeNewswire)
Aug-06-24 06:30PM	Aquestive Therapeutics (AQST) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates (Zacks)

Aquestive Therapeutics, Inc. engages in the identifying, developing, and commercializing differentiated products to address unmet medical needs and to solve patients' therapeutic problems. Its product pipeline include Libervant, AQST-108, AQST-305, Suboxone and Zuplenz. The company was founded in January 2004 and is headquartered in Warren, NJ.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Carl N. Kraus	Affiliate	Nov 17 '25	Proposed Sale	5.39	53,100	286,209		Nov 17 04:39 PM
Jung Cassie	Chief Operating Officer	Oct 15 '25	Option Exercise	3.10	25,000	77,568	308,346	Oct 17 02:01 PM
Jung Cassie	Chief Operating Officer	Oct 15 '25	Sale	7.01	67,575	473,701	240,771	Oct 17 02:01 PM
Kraus Carl N	Chief Medical Officer	Oct 15 '25	Sale	7.00	20,272	141,904	282,475	Oct 17 02:01 PM
Boyd Peter E.	See Remarks	Oct 15 '25	Sale	7.00	10,000	70,000	268,323	Oct 17 02:00 PM
Carl N. Kraus	Officer	Oct 15 '25	Proposed Sale	6.88	40,544	278,943		Oct 15 04:45 PM
CASSIE JUNG	Officer	Oct 15 '25	Proposed Sale	6.88	67,575	464,916		Oct 15 04:34 PM
Peter Boyd	Officer	Oct 15 '25	Proposed Sale	7.00	10,000	70,000		Oct 15 12:24 PM
Barber Daniel	President and CEO	Sep 26 '25	Sale	6.03	91,343	551,191	923,430	Sep 29 04:26 PM
Boyd Peter E.	See Remarks	Sep 26 '25	Sale	6.30	10,000	63,000	278,323	Sep 29 04:26 PM
Peter Boyd	Officer	Sep 26 '25	Proposed Sale	6.30	10,000	63,000		Sep 29 04:05 PM
DANIEL BARBER	Director	Sep 26 '25	Proposed Sale	5.26	91,343	480,464		Sep 26 04:32 PM
Barber Daniel	President and CEO	Sep 19 '25	Sale	6.00	400	2,400	1,014,773	Sep 22 05:25 PM
DANIEL R BARBER	Officer	Sep 19 '25	Proposed Sale	4.94	400	1,976		Sep 19 04:45 PM
Jung Cassie	Chief Operating Officer	Sep 04 '25	Option Exercise	1.93	50,000	96,408	345,526	Sep 08 07:06 PM
Jung Cassie	Chief Operating Officer	Sep 04 '25	Sale	5.00	62,180	310,900	283,346	Sep 08 07:06 PM
Boyd Peter E.	See Remarks	Sep 05 '25	Sale	5.30	15,000	79,500	288,323	Sep 08 05:13 PM
Boyd Peter E.	Officer	Sep 05 '25	Proposed Sale	5.30	15,000	79,500		Sep 05 10:32 AM
CASSIE JUNG	Officer	Sep 04 '25	Proposed Sale	3.95	62,180	245,611		Sep 04 04:26 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

Aquestive Therapeutics Inc

Upgrade your FINVIZ experience